You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Colorcon
AstraZeneca
Moodys
Merck

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,765,399

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,765,399
Title:Mutations in the epidermal growth factor receptor gene
Abstract: The invention relates to a new identified mutation in the epidermal growth factor receptor gene, leading to an amino acidic change which highly correlates with the resistance to a therapy regimen comprising cetuximab and the sensitivity to a therapy regimen comprising panitumumab. The invention includes peptide sequences, primers and probes to detect such a mutation, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab and/or panitumumab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer and to head and neck cancer.
Inventor(s): Montagut Viladot; Clara (Barcelona, ES), Albanell Mestres; Joan (Barcelona, ES), Rovira Guerin; Ana (Barcelona, ES), Bellosillo Paricio; Beatriz (Barcelona, ES), Dalmases Masseg ; Alba (Barcelona, ES)
Assignee: FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES)
Application Number:14/236,614
Patent Claims:see list of patent claims

Details for Patent 9,765,399

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES) 2031-08-03 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES) 2031-08-03 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES) 2031-08-03 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial FUNDACIO INSTITUT MAR D\'INVESTIGACIONS MEDIQUES (IMIM) (Barcelona, ES) 2031-08-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Boehringer Ingelheim
AstraZeneca
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.